



Photocyclization of a naphthyl substituted Y-enyne^{†,‡}

Bilal R. Kaafarani,^a Brigitte Wex,^a Jeanette A. Krause Bauer^b and Douglas C. Neckers^{a,*}


^aCenter for Photochemical Sciences, Bowling Green State University, Bowling Green, OH 43403, USA

^bDepartment of Chemistry, University of Cincinnati, Cincinnati, OH 45221, USA

Received 14 August 2002; revised 16 September 2002; accepted 18 September 2002

Abstract—Y-enyne **1** undergoes electrocyclic ring closure, via a cumulene intermediate **2**, to photoproduct **3** upon irradiation at 350 nm in the presence/absence of air. In non-polar solvents, a [1,5] H-shift affords the photoproduct. In MeOX (X=H/D), protonation/deuteration of the central allenic carbon in **2** occurs. The X-ray structure of **3**, the photoproduct upon irradiation of **1** in benzene, is reported. © 2002 Elsevier Science Ltd. All rights reserved.

Interest in antitumoral activity of enediynes has increased recently and calicheamicin and esperamicin have been tested clinically.¹ Bergman² cyclization of enediynes (**A**) was reported to play a key role in such enediyne antitumor drugs.³ After a trigger reaction (cyclization is not spontaneous) brings the edges of the enediyne with its six conjugated π electrons into sufficient proximity, cyclization takes place *in vivo* forming active diyl radicals, which subsequently interact with macromolecule targets.⁴



Unlike linear enediynes, cross-conjugated enediynes (Y-enynes), **B** cannot undergo Bergman cycloaromatization because five carbon atoms with only five π electrons are involved, and this is insufficient for aromatization. However, under reductive conditions cyclization may be possible generating a product with a Hückel number of $(2n+2)$ π electrons.⁵

Tinnemans and Laarhoven first reported the photocyclization of enynes⁶ proposing a radical mechanism⁷ in non-polar solvents (hexane and benzene) and an ionic mechanism in methanol. In a subsequent paper in the series, Van Arendonk⁸ et al. proposed a 1,2,4-cyclohexatriene derivative formed from the singlet-excited *cis*-1,4-diaryl-butenyne as the primary reaction intermediate. This led to a product either via a radical intermediate, an ionic intermediate or under an argon atmosphere directly by intramolecular hydrogen shift. Previously, we reported that photocyclization occurred when the Y-enyne was substituted with a naphthyl group (Scheme 1).⁹ We suggested photocyclization of **1** occurred entirely via an intermediate cumulene, **2**, in methanol, hexane and benzene under both argon and air (Scheme 1).⁹

The photoreaction of **1** in C_6D_6 was followed by ¹H NMR (Fig. 1). The starting material **1** shows two distinct peaks (Fig. 1a). The most downfield peak, a broad singlet due to *meta* coupling with H_c , is assigned to H_a . H_c is a doublet of doublets (*ortho* coupled to H_d and *meta* coupled to H_a ; $J_{meta}=1.4$ Hz). Irradiation at 350 nm in benzene caused four new peaks to appear (Fig. 1b). Eventually, the two peaks corresponding to the starting material disappeared affording photoproduct **3** (Fig. 1c). In **3**, H_b and H_c are *meta* coupled ($J_{meta}=1.4$ Hz), while H_c is coupled to H_d and is therefore a doublet. Similar results were observed when **1** was irradiated in C_6H_6 , C_6D_6 , C_6H_{14} , and C_6D_{14} , indicating that these solvents are not involved in the photoreaction. Irradiation of **1** in CH_3OD led to deuterium incorporation. The H_b peak in the photoproduct observed upon irradiation in CH_3OH , a doublet *meta* coupled with H_c (same as in Fig. 1c), became a singlet

Keywords: Y-enyne; photocyclization; cumulene; [1,5] H-shift; X-ray structure.


* Corresponding author. Tel.: 419-372-2034; e-mail: neckers@photo.bgsu.edu

[†] This paper is dedicated to Professor Dr. J. W. Neckers on the occasion of his 100th birthday.

[‡] Contribution # 468 from the Center for Photochemical Sciences.

upon irradiation of **1** in CH₃OD (photoproduct **4**). This was accompanied by the disappearance of the H_e peak (Fig. 1d). GC/MS (DIP) indicated a MW of 355 (MW of **3** is 354). No deuteration was observed when irradiation was carried out in CD₃OH. In MeOX (X=H/D), protonation/deuteration of the central allenic carbon in **2** afforded the photoproduct **3/4** (path i of Scheme 1). In non-polar solvents, a [1,5] H-shift afforded the photoproduct (path ii of Scheme 1). Irradiation of **1a**

(>95% D incorporation) in hexane led exclusively to **4** (>95% D incorporation).¹⁰ This confirmed the proposed [1,5] H-shift via the cumulene intermediate **2**.⁹ The photocyclization formed phenanthrene rather than anthracene (Fig. 2a). MOPAC and SPARTAN calculations showed the absence of electron density over the γ position of the naphthalene (Fig. 2b) in **1** in both the HOMO (highest occupied molecular orbital) and LUMO (lowest unoccupied molecular orbital), explain-



Scheme 1. Proposed mechanism for photocyclization of **1**.




Figure 1. ¹H NMR (200 MHz) spectra of **1** in C₆D₆ upon 350 nm irradiations. Irradiation time is (a) 0 h, (b) 13 h, (c) 32 h (photoproduct **3**). (d) ¹H NMR spectrum of **4** dissolved in C₆D₆.




Figure 2. (a) Specificity of the photoreaction. (b) HOMO and LUMO of **1**.




Figure 3. (a) ORTEP of **3** at 150 K (ellipsoids at 50% probability). (b) Stacking of **3**.

ing the specificity of this photoreaction. α -Cyclization¹¹ in naphthalene substituted ethylenes was supported by molecular orbital calculations.

X-Ray¹² analysis of **3**, the photoproduct formed upon irradiation of **1** at 350 nm in benzene, confirms its chemical structure (Fig. 3a). We noticed that **3** molecules pack along the *b* axis of the unit cell where they appear as ribbons of molecules, separated by 4 Å (intermolecular π - π interactions between the phenanthryl rings) (Fig. 3b).

Acknowledgements

B.R.K. thanks the McMaster Endowment for a research fellowship. This work was supported by NSF (Grant # DMR-0091689).

References

- (a) Schor, N. F. In *Cancer Therapeutics: Experimental and Clinical Agents*; Teicher, B., Ed.; Humana Press:

- Totowa, NJ, 1996; pp. 229–240; (b) Schmitt, D. A.; Kisanuki, K.; Kimura, S.; Oka, K.; Pollard, R. B.; Maeda, H.; Suzuki, F. *Anticancer Res.* **1992**, *12*, 2219; (c) Takahashi, T.; Yamaguchi, T.; Kitamura, K.; Noguchi, A.; Mitsuyo, H.; Otsuji, E. *Jpn. J. Cancer Res.* **1993**, *84*, 976; (d) Lee, M. D.; Durr, F. E.; Hinman, L. H.; Haman, P. R.; Ellestad, G. A. In *Advances in Medicinal Chemistry*; Maryanoff, B. E.; Maryanoff, C. A., Eds.; Greenwich, CT: Jai Press, 1993; Vol. 2.
- (a) Jones, R. R.; Bergman, R. G. *J. Am. Chem. Soc.* **1972**, *94*, 660–661; (b) Bergman, R. G. *Acc. Chem. Res.* **1973**, *6*, 25–31; (c) Lockhardt, T. P.; Commita, P. B.; Bergman, R. G. *J. Am. Chem. Soc.* **1981**, *103*, 4082–4090.
- (a) Nicolaou, K. C. *Angew. Chem., Int. Ed. Engl.* **1993**, *32*, 1377–1385 and references cited therein; (b) Hitchcock, S. A.; Chu-Moyer, M. Y.; Boyer, S. H.; Olson, S. H.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1995**, *117*, 5750–5756.
- (a) Smith, A. L.; Nicolaou, K. C. *J. Med. Chem.* **1996**, *39*, 2103–2117 and references cited therein; (b) Jones, L. H.; Harwig, C. W.; Wentworth, P.; Simeonov, A.; Wentworth, A. D., Jr.; Py, S.; Ashley, J. A.; Lerner, R. A.; Janda, K. D. *J. Am. Chem. Soc.* **2001**, *123*, 3607–3608 and references cited therein.

5. Eshdat, L.; Berger, H.; Hopf, H.; Rabinovitz, M. *J. Am. Chem. Soc.* **2002**, *124*, 3822–3823 and references cited therein.
6. Tinnemans, A. H. A.; Laarhoven, W. H. *Tetrahedron Lett.* **1973**, *14*, 817–820.
7. Tinnemans, A. H. A.; Laarhoven, W. H. *J. Chem. Soc., Perkin Trans. 2* **1976**, 1111–1115.
8. Van Arendonk, R. J. F. M.; Fournier de Violet, Ph.; Laarhoven, W. H. *J. R. Neth. Chem. Soc.* **1981**, *100*, 256–262.
9. Kaafarani, B. R.; Neckers, D. C. *Tetrahedron Lett.* **2001**, *42*, 4099–4102.
10. Spectroscopic data of **1**, **3**, and **4** are reported in Ref. 9.
11. Scholz, M.; Muehlstaedt, M.; Dietz, F. *Tetrahedron Lett.* **1967**, *8*, 665–668.
12. The crystallographic data is deposited at the Cambridge Crystallographic Data Center (CCDC # 191506).